info@trade-jp.net
menu
News / Blog
May Holidays 2026 - Pay Attention!
Catalog
Asverin tablets 20 mg from Japan for cough
Product Code :
Availability : Out Of Stock
USD 29.90
General information on Japanese Asverin tablets 20 mg for cough
Package details: 100 tablets
Manufacturer: Nipro ES Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Japan
Active ingredient: tipepidine hibenzate (chemical formula C15H17NS2)
Medical effect: Asverin tablets are effective for following aims and objectives:
- improvement of cough symptoms with cold,
- suppressing cough in patients with bronchitis,
- making expectoration of phlegm easier,
- reducing excessive mucus and phlegm.
Contraindications and precautions: do not use for pregnant or breastfeeding women. If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Japanese Asverin tablets 20 mg for cough
For adults, take 1 or 2 tablets (22.14-44.28 mg of the active ingredient) at a time, 3 times a day. The consulting doctor may adjust the dosage according to age and symptoms.
How effective are Japanese Asverin tablets 20 mg for cough?
Asverin tablets contain tipepidine hibenzate, also known as tipepidine. It’s a synthetic non-opioid thiambutene working as antitussive and mucoactive agent. Asverin tablets reduce coughing and make easier the expectoration of the phlegm.
Who should use Asverin tablets 20 mg from Japan?
Tipepidine hibenzate has been used in Japan and other Asian countries since 1959. It’s safe, generally well-tolerated, has no particular contraindications. That’s why Asverin tablets can be used for relieving cough even in patients with various chronic diseases. While an allergic reaction still may occur, Japanese researchers note that there were only 2 recorded cases of the anaphylaxis caused by tipepidine (E. Mochizuki, T. Shirai et al. Anaphylaxis caused by tipepidine hibenzate, a central antitussive drug. Respirology Case Reports, 2015, March, 3(1): 3–5).
